Annual Report and Financial Statements for the year ended 31st March 2023
## On the cusp of change
**Annual Report** and **Financial Statements** for the year ended 31st March 2023
1
Annual Report and Financial Statements for the year ended 31st March 2023
Contents
## Contents
## **Overview**
On the cusp of change
4
## **Trustees Report (incorporating strategic report)**
Goal 1: To bring about critical breakthroughs in 8 early diagnosis and treatment research Goal 2: To transform care, everywhere 16 Goal 3: To increase access to, and engagement 23 with, our services
## Who we are
## Our values
Our vision Our mission Our values Everyone with We lead the fight **·** Compassion pancreatic cancer against pancreatic **·** Integrity survives to live long cancer **·** Determined and well **·** Pioneering
Goal 4: To reposition our organisation to best support 30 breakthroughs in pancreatic cancer
**Structure, governance and management** 35 **Financial review** 41 **Independent Auditor’s Report** 46
## **Pancreatic cancer is a tough one.**
It’s tough to treat, tough to diagnose, tough to research and tough to survive.
We’re here for people today, and we’re demanding a better future.
Together, we can transform the future for everyone affected by pancreatic cancer.
3
2
On the cusp of change
Annual Report and Financial Statements for the year ended 31st March 2023
## On the cusp of change
**----- Start of picture text -----**
Diana Jupp
**----- End of picture text -----**
In the past year, thanks to incredible support from people like you, our impact for people affected by pancreatic cancer has been greater than ever. Although, as you may sadly know, pancreatic cancer is still the toughest of cancer challenges - and remains a cancer emergency - with your help, progress is coming. We want to take a moment to reflect on what we achieved together last year, and what we can continue to achieve together as we embark on our ambitious new strategy.
Because of people like you, with funding from Pancreatic Cancer UK:
- Professor George Hanna and his team at Imperial College London are currently developing a world-first breath test enabling GPs to detect pancreatic cancer early
**----- Start of picture text -----**
Eleanor Phillips
**----- End of picture text -----**
- Dr Petros Mouratidis at the Institute of Cancer Research is leading pioneering research into the use of ultrasound and immunotherapy to treat pancreatic cancer
- Leading UK healthcare professionals are working with us to define the best patient experience for people with pancreatic cancer
- People who have just been diagnosed with pancreatic cancer have access to specialist, personalised support from our dedicated nursing team
As you will read in our annual report, these activities and many more, have been made possible because in 2022/23 you helped us to raise more money than ever before – over £11.5million.
Momentum for our cause is growing, as more people become aware of the injustices that have faced people with pancreatic cancer. An incredible 86,419 new supporters joined us last year to help make a difference, whether through fundraising, campaigning, volunteering or raising awareness on social media.
Because of this, together we were able to accelerate progress for people affected by pancreatic cancer by funding more research, providing more support and influencing more change. Now, we have an ambitious new five-year strategy, which we can only achieve with your support. So, if you are a researcher with a bright idea, please get in touch. If you’re a charitable trust or foundation looking for a cause to support, look no further. If you want to commit to our cause by working for us, please apply. If you want to raise money or volunteer, please let us help you and know that your support will make the world of difference.
We want to take a moment to thank all our staff and trustees, past and present, who have helped make this happen. Lynne Walker stepped down as chair and Stuart Fletcher and Daniel Benjamin both resign from the board this year, having reached the end of their tenure. All have played an immensely important role over the years. We are thrilled to have Iain Frame, Anne Tutt and Jeremy Hand join our board.
And a huge thank you to our ambassadors, philanthropists, fundraisers and volunteers who make all our ambitions possible.
Last year, like every year, we lost too many people to this devastating disease. Many played an active role campaigning and fundraising for our charity. They embodied everything we stand for and believe in as a charity. Optimism, energy, heart and an utter determination to find the answer to early diagnosis and treatment. It’s up to us to continue this legacy – together our voices will be so loud they cannot be ignored.
Thank you for everything you have done so far. We hope that you will join us as we embark on this ambitious new strategy, to help bring about the transformation in survival rates that we dream of. Because together, we will find breakthroughs, give hope and save lives.
Together we were able to accelerate progress for people affected by pancreatic cancer by funding more research, providing more support and influencing more change.
5
4
HENKE-
EHXE.JECT'
11
GL
anli -ati
an
45
Annual Report and Financial Statements for the year ended 31st March 2023
Goal
**----- Start of picture text -----**
Goal 01
**----- End of picture text -----**
01 To bring about critical breakthroughs in early diagnosis and treatment research
## **Why this work is so important**
**Research saves lives, which is why Pancreatic Cancer UK has invested £12.25 million in research to date.** Our researchers are pushing the boundaries of what’s possible by using cutting-edge technologies to improve early detection of pancreatic cancer, monitor people who are most at risk, and pioneer promising new therapies to make better treatment a reality.
Alongside this, **we invest in the research leaders of tomorrow to accelerate life-saving breakthroughs** .
## **Working to save lives through early detection and diagnosis**
There are still no simple tests to detect pancreatic cancer, so 80% of people with the disease are diagnosed at a late stage and miss the chance to have potentially life-saving treatment. Our Early Diagnosis Research Alliance has laid the groundwork for potentially game-changing ways to detect pancreatic cancer earlier.
This year, we invested in **the world’s first** breath test **for pancreatic cancer** devised by a team at Imperial College London, led by Professor George Hanna. The **first blood test** for the disease, also developed through the Early Diagnosis Research Alliance, is being tested in the USA. Together, these exciting developments could save thousands of lives every year by helping GPs to identify people who urgently need further tests.
Health Minister Helen Whately with our Head of Research, Dr Chris Macdonald and Professor George Hanna
## **2022/23 in numbers**
**We invested more than ever in research, an incredible £2.2m in grants, and £1m in research support**
**Over 400 people affected by pancreatic cancer are helping to shape our research activities**
**Every £1 that we invest in research generated another of support from £7 other funders**
**We’ve invested £12.25m in research to date**
9
8
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 01
distinguish pancreatic cancer from other conditions.
We’re investing in projects to identify and refine blood markers that could be early signals of pancreatic cancer. Dr Pilar Acedo at University College London is investigating whether proteins produced by pancreatic cancer cells and microorganisms in the pancreas could be combined to help
We’re also supporting Dr Patrick Kierkegaard at Imperial College London to explore the support that GPs need to start using new pancreatic cancer tests as soon as they become available.
**----- Start of picture text -----**
Dr Pilar Acedo, a
Pancreatic Cancer UK
Career Progression Fellow
**----- End of picture text -----**
## **Investing in improved treatment and care**
**and immunotherapy** could improve treatment outcomes for people with pancreatic cancer.
Unfortunately, pancreatic cancer remains difficult to treat. Immunotherapy has revolutionised the treatment of some other cancers but does not work as well on pancreatic cancer. We’ve awarded a Career Progression Fellowship to Dr Petros Mouratidis at the Institute of Cancer Research to investigate whether **combining histotripsy, a cutting-edge technique that targets pancreatic cancer cells through highly focused ultrasound**
Through our Research Innovation Fund, we’re supporting Professor Eric O’Neill and his team at the University of Oxford to explore whether a **novel radiotherapy** technique could help to treat pancreatic tumours, and the best way to combine this with immunotherapy for more effective treatment.
## **Developing future pancreatic cancer researchers**
The app gathers anonymised, national and regional data on people’s quality of life, treatment and care pathways to inform UK-wide clinical recommendations. Medli has received praise from healthcare professionals and researchers and has already been included in a research proposal to enable remote tracking of patients’ experiences. Medli will also help people living with pancreatic cancer in various ways (see page 25).
To accelerate urgently needed breakthroughs in pancreatic cancer detection and treatment, we need more pancreatic cancer researchers.
That’s why our Career Progression Fellowships support talented researchers with significant pancreatic cancer research experience to become independent researchers. This funding also helps them take time away from their clinical and teaching responsibilities to concentrate on research. To date, we’ve progressed the careers of over 25 early-stage researchers through schemes such as this.
We’re working with NHS England to help enrol people at high risk of pancreatic cancer onto the **Pancreatic Cancer Hereditary Risk Register** . Regular monitoring through this programme will help to spot any worrying changes early, enabling people to access earlier treatment and increase their chances of surviving pancreatic cancer. We are working to secure long term investment and rollout of this programme across the UK.
## **Improving patient data and experiences**
Experience from other types of cancer shows that more robust and in-depth evidence leads to improvements for patients. We **launched our** Medli app to improve access to pancreatic cancer clinical and treatment data, and patient-reported experiences and outcomes.
11
10
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 01
## **Table 1: Research grants we awarded in 2022/23**
**----- Start of picture text -----**
Lead Researcher Project Description Amount
Professor George Hanna, Developing a breath test to speed up the detection
£651,836.00
Imperial College London of pancreatic cancer
Dr Petros Mouratidis, Using ultrasound and immunotherapy to treat
£299,992.73
The Institute of Cancer Research pancreatic cancer
Dr Pilar Acedo, Investigating blood proteins and microorganisms
£299,999.14
University College London to detect pancreatic cancer earlier
Professor Eric O’Neill, Using a new type of immune cell to improve
£99,890.00
University of Oxford pancreatic cancer treatment
Professor Axel Behrens, Uncovering signature molecules to detect
£100,000.00
Institute of Cancer Research treatment resistance in pancreatic cancer
Understanding how pancreatic lesions become
Dr Fieke Froeling,
cancerous to support early diagnosis and timely £97,863.35
University of Glasgow
surgery
Dr Kirsteen Campbell, Cancer
Improving pancreatic cancer therapies £98,008.00
Research UK Beatson Institute
Developing a toolkit to assess GPs’ readiness to use
Dr Patrick Kierkegaard,
new tests to screen and monitor people at high risk £95,509.23
Imperial College London
of pancreatic cancer
Maintaining the Pancreatic Cancer Risk Register
Professor Christopher Halloran,
to help improve our understanding of inherited £200,000.00
University of Liverpool
pancreatic cancer risk
Developing a biobank of samples from people with
Professor Stephen Pereira, vague symptoms which may or may not be pancreatic
£300,000.00
University College London cancer, to support the development of new tools for
earlier detection and diagnosis
**----- End of picture text -----**
## **Case Study**
## **Professor George Hanna**
## **Head of the Department of Surgery and Cancer, Imperial College London**
In a world-first for the disease, a research team at Imperial College London led by Professor George Hanna are studying how breath samples taken in a GP surgery could ensure people with early pancreatic cancer symptoms, which are often mistaken for other less serious health conditions, are instead rapidly referred for scans and lifesaving treatment.
“The best route to improve cancer survival is early cancer detection. This work to develop a breath test builds on work done by Pancreatic Cancer UK. This project is exciting because it will allow us to detect cancer at an early stage with a simple test. I expect the next five years will be really quite transformational for pancreatic cancer detection.”
**“**
I expect the next five years will be really quite transformational.
13
12
atKG
ancei
Annual Report and Financial Statements for the year ended 31st March 2023
**----- Start of picture text -----**
Goal 02
**----- End of picture text -----**
## Goal
## 02 To transform care everywhere
## **2022/23 in numbers**
**12**
**52,436**
**people signed our No Time to Wait petition to demand faster diagnosis and treatment**
**Cancer Alliances now implement diagnostic pathways for pancreatic cancer, thanks to guidance that we** ~~**helped develop**~~
**130**
**We invested £1.8m in campaigning and raising awareness**
**MPs, peers and MSP’s participated in No Time to Wait and Pancreatic Cancer Awareness Month events**
## **Why this work is so important**
**Sadly, the UK still lags behind the rest of the world in pancreatic cancer care and treatment outcomes.** We won’t stand for this, and we’re fighting to change it.
In 2022/23, Pancreatic Cancer UK **influenced governments, opposition parties and NHS bodies across the UK to increase their focus on pancreatic cancer.** We are determined to drive improvements in diagnosis, treatment and care across the UK through this approach. Together with our amazing supporters, we **influenced the development and publication of national cancer plans and strategies across UK nations** to meet the needs of people living with pancreatic cancer.
## **Working towards earlier and faster diagnosis**
We **work with healthcare professionals to standardise best practice** and improve the treatment received by people with pancreatic cancer.
In England, we collaborated with NHS England to review recommendations **to speed up diagnosis** to 21 days or less and helped design a **national NHS pancreatic cancer diagnosis guide,** due to be published soon. This will be critical to ensuring that people living with this tough disease get timely access to supportive care and the best available treatment, to improve their quality of life and their chances of surviving. In Scotland we collaborated with NHS Scotland on their new pilot pathway to accelerate pancreatic cancer diagnoses, which is now operational.
## **Driving improvements in treatment and care**
As part of our commitment to ensure better, faster treatment and care everywhere, since 2021 we’ve been working with around 250 health professionals and people with lived experience of pancreatic cancer to agree on **what a better, fairer standard of care** care should look like across the UK - from the point of diagnosis onwards. As part of this, in the last year we have been strengthening our understanding of what good pancreatic cancer care involves and started preparing a report to communicate recommendations to the government.
We’re also playing a leading role in shaping **NHS England’s first comprehensive review of pancreatic cancer services** (Getting It Right First Time), which aims to improve and standardise treatment and care across the country. In addition, we’re helping to design and deliver the first **National Clinical Audit on pancreatic cancer.** The Royal College of Surgeons will use audit findings to develop indicators to measure the quality of care people receive.
Pancreatic cancer affects the mental health of both people living with the disease and their loved ones. In 2022, we developed the first guide containing evidence-based recommendations to improve psychosocial support for these people. Now included in a toolkit for cancer alliances in England, this guide will help anyone affected by pancreatic cancer to access the right **psychosocial support** as soon as they need it.
Pancreatic enzyme replacement therapy (PERT), also known as Creon[®] , Pancrease[®] , Nutrizym[®] or Pancrex[®] can help people who have pancreatic cancer to digest food, improving their quality of life and helping them to build up strength ready for treatment.
17
16
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 02
Through our **Transform Lives: Prescribe campaign** we continued to push the NHS to make PERT more widely available to people with pancreatic cancer.
As a result, PERT prescription levels across Scotland will be measured for the first time. This will ensure that everyone in Scotland who needs it is offered this simple tablet that can make such a difference to people’s lives.
## **Influencing and driving change throughout the UK**
In response to our concern the NHS winter crisis causing shocking treatment delays even worse for some people with pancreatic cancer, we launched the latest phase of our **No Time To Wait campaign.** This campaign called on all four governments across the UK to deliver faster diagnosis and treatment, because people with pancreatic cancer can’t wait. As a result, we secured meetings with cancer ministers in England, Scotland and Northern Ireland, and 1,800 of our supporters invited their parliamentary representatives to listen to our concerns.
In 2022/23, we raised the profile of pancreatic cancer with governments across the UK to drive improvements in diagnosis, treatment and care. We worked with parties from across the political spectrum to ensure they better understand the scale of the pancreatic cancer emergency and actions they need to take to tackle it.
19
18
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 02
**----- Start of picture text -----**
Joining forces with
One Cancer Voice
**----- End of picture text -----**
To amplify our voice and impact, we often campaign as part of cancer coalitions and alliances. In January 2023, the UK Government replaced its planned 10-year Cancer Plan with a new Major Conditions Strategy. In response, we joined forces with over 60 charities through the **One Cancer Voice** coalition to call for world-class cancer services to dramatically improve the experiences of people affected by cancer. Altogether, 76,559 people signed our petition.
over the next decade including a patient advocate meeting with the cancer minister. In **Scotland,** Pancreatic Cancer UK also secured meetings with the Cabinet Secretary for Health, the Minister for Public Health and government cancer teams, and participated in multiple events and consultations. Our annual Scottish Parliament Pancreatic Cancer Awareness Month debate also helped to keep pancreatic cancer on MSPs’ agendas.
We chair the **Scottish Cancer Coalition’s Earlier Diagnosis and Screening subgroup.** In 2022/23, we influenced Scotland’s Earlier Cancer Diagnosis Vision and action plan and collaborated on a cancer awareness campaign.
In 2022/23 we continued to chair the **Less Survivable Cancers Taskforce** to raise awareness of tough, often overlooked,cancers among parliamentarians and the media, and demand change. This taskforce conducted a UK-wide survey which found that the public knows worryingly little about these cancers’ symptoms. And for the first time it **attended party political conferences** to strengthen relationships with the major political parties, which is vital in securing change.
As part of the **Wales** Cancer Alliance, we contributed to the Welsh Government’s Cancer Improvement Plan and ensured it mentions less survivable cancers. And we influenced **Northern Ireland’s** 2022 cancer strategy by participating in working groups. We met with Peter May, the Permanent Secretary at the Department of Health in **Northern Ireland** , to discuss how to improve pancreatic cancer treatment and care.
The taskforce worked with the Scottish Cancer Coalition and people affected by pancreatic cancer to **influence the forthcoming Scottish Cancer Strategy** , to prioritise less survivable cancers
## **Case Study**
## **Mihika from East Sussex**
Based on her and Jay’s experience, Mihika stood with us and thousands of others around the UK to fight for early diagnosis through our Unite, Diagnose, Save Lives campaign.
“Jay had to go through so much before they diagnosed him. He made about a dozen phone calls to the GP. About a year before his diagnosis, everything was giving him really bad reflux, stomach pains. Then he started bloating after eating, and couldn’t keep food down.
A new GP sent him for a CT scan but pancreatic cancer had already spread to his liver. The doctor said with chemo, it would be three to six months. It was gut-wrenching. Everything had just been ripped away, all the plans we had. We were going to have a second child.
Jay died on 20 February 2022, aged 46. He could have lived longer or been able to do more if he’d been diagnosed earlier. It would be amazing to have an early detection test. Jay didn’t want this to happen to anyone else.”
## **See page 37 for more about this campaign.**
**“** Jay could have lived longer or been able to do more if he’d been diagnosed earlier. It would be amazing to have a quick [early detection] test.
21
20
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 03
Goal
03 To increase access to, and engagement with, our services
## **2022/23 in numbers**
**Our online support sessions and webinars for those affected by pancreatic cancer were attended 378 times**
**Our specialist pancreatic cancer nurses responded to more than**
**848,137 people accessed our online information**
**5,000 calls and emails**
**We invested £2m in our information and support services**
**1,287 healthcare professionals attended our training sessions and online courses**
## **Why this work is so important**
## **Reaching more people with vital information**
A diagnosis of pancreatic cancer can be a terrible shock. Through **Pancreatic Cancer UK’s free information and support services** , we help people with pancreatic cancer and their families know what to expect, understand their diagnosis, treatment and care options, and get to know others in similar situations.
In 2022/23 we continued to help more people affected by pancreatic cancer access the information and support they need. Overall, we distributed 28% more copies of our most popular resource, on managing the dietary symptoms of pancreatic cancer. This helps people manage digestion problems properly, which may help improve their quality of life.
Our **guidance, training and events for healthcare professionals** give clinicians access to the latest evidence and best practice in relation to pancreatic cancer, so they can offer people effective treatment and care.
300,535 people accessed our symptoms web page – 30% more than in 2021/22, and we distributed more than four times as many awareness-raising materials as in the previous year. Greater awareness can encourage people to discuss worrying symptoms with their doctor, potentially leading to earlier diagnosis.
23
22
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 03
## **Providing invaluable support**
In 2022/23 our specialist pancreatic cancer nurses supported **1,958 people through our free** Support Line, via practical and emotional support. This gives people the knowledge and confidence to manage their symptoms, treatment plan and any side effects, improving their quality of life. For instance, 92% of people felt more able to make decisions about treatment and care after contacting our Support Line.
Our online services help to reach people wherever and whenever they need us. In 2022/23 **our online** support sessions, on topics such as coping with symptoms and managing nutrition, helped people to navigate their experience of pancreatic cancer. Participants told us this helped them feel less alone, more able to manage their symptoms, and able to make informed decisions about their treatment. And 100% of family members or friends who joined an online session said it helped them feel less alone and better informed about their loved one’s diagnosis.
During the year, 210 new people signed up to our online forum, a supportive space for anyone affected by pancreatic cancer to discuss the practical and emotional issues they face.
Many people affected by pancreatic cancer don’t know anyone in a similar situation, which can be isolating. Our **peer to peer support services** help people to meet others who have had similar experiences in ways that suit their needs – ranging from one off chats to long term, mutual support.
Our **in-depth** Side by Side **telephone peer support service,** for people who have had or are about to have pancreatic cancer surgery, supported 29 new people in 2022/23. All of them said that this gave them a better understanding of what to expect from surgery. Volunteers who have had pancreatic surgery also supported people currently living with the disease through **informal, virtual ‘cuppa’ sessions.** Similarly, relatives and carers of people with pancreatic cancer received support from volunteers who have been in their shoes.
Lisa, one of the specialist nurses on our Support Line
## **New information and support services**
This year we launched Medli, **a gamechanging app** to help people living with pancreatic cancer access information and support tailored to their circumstances. The app also enables people to record their appointments, medication, symptoms and treatment side effects in one place. As well as making life easier at a challenging time, this will enable people to have evidence based discussions with their healthcare team to choose the best course of action.
As a result of the initial launch, 122 people started using the app, which has received many positive reviews from people living with pancreatic cancer and their friends and relatives.
## **“**
Having all your information in one place [in the Medli app] is just amazing. It’s all in the palm of your hand. The convenience of having that is key for cancer patients.”
## **Medli app user**
25
24
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 03
## We launched new information and support emails for people recently
diagnosed with pancreatic cancer to help them navigate information and support available. These emails are tailored to each person’s diagnosis, or to family members. They guide people through key information, from managing symptoms to treatment options, in bite sized chunks. In its first three months, this service provided bespoke support to 26 people living with pancreatic cancer and 86 family members, with two thirds of recipients being supported by us for the very first time.
## **“**
These emails are brilliant. At such a difficult time, people need to have information in plain terms [that is] easy to follow and understand.”
## **Engaging health professionals online**
In 2022/23 we **reached more health professionals than ever** with specialist information and training on pancreatic cancer treatment and care. We ran 10 virtual events on various topics, reaching professionals across the UK. An impressive 100% of attendees said they would recommend our events to others. Among those who gave feedback, 90% said they had increased their knowledge after attending one of our events.
Our online **introduction to pancreatic cancer course and our guide on PERT** engaged 59% more health professionals than in previous years. Overall, 667 healthcare professionals completed one of these courses, and 98% said this had increased their knowledge.
## **Case Study**
## **Linda from Cumbria**
Linda has been using our services since she was diagnosed
with pancreatic cancer in 2021.
“The Support Line is so much more than support. Each and every nurse is so friendly, compassionate and extremely knowledgeable in all aspects of pancreatic cancer. Any concerns regarding treatment, side effects of chemo, managing Creon etc are addressed immediately either through a phone call or email.
It is so reassuring and a comfort to know that help from Pancreatic Cancer UK and information they can give about other services is always available. This impacts positively on mental, emotional and spiritual wellbeing.
It has helped getting to know the nurses and feeling like they have become caring friends.
It has taken away much of the fear about trying to cope alone. When things do become overwhelming, after a chat with a nurse, things seem less bleak, and it makes one feel stronger to deal with the inevitable obstacles on an unknown journey.”
## **“**
**Karen, a former pancreatic cancer patient who helped develop our information and support emails**
Clinical trials can be an important treatment option for people with pancreatic cancer. Our **new Trial Finder** searches all pancreatic cancer trials in the UK and provides key facts about each one in simple language. This helps people with pancreatic cancer and their healthcare teams decide whether a trial is suitable for them.
This course has helped me to be able to understand better the stages of pancreatic cancer and the prognosis, as well as understanding better the investigations that need to be followed.”
## **GP practice dietitian**
**“** It has taken away much of the fear about trying to cope alone.”
27
26
Pancreatic
Cancer
Our researchers are
pushing the boundaries
of what's possible.
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 04
Goal
04
To reposition our organisation to best support breakthroughs in pancreatic cancer
## **2022/23 in numbers**
**We achieved 1,219 pieces of print, online or broadcast coverage, with a potential reach of**
**86,419**
**new supporters joined us this year and our following across our social media channels grew by 8%**
**million 881 people**
**An amazing**
**Our incredible supporters raised £11.5m**
**£1.3m**
**was raised from the two TCS London Marathons that took place just 6 months apart**
**in 2022/23**
## **Why this work is so important**
Pancreatic Cancer UK’s achievements are made possible because of our incredible supporters and everyone in the pancreatic cancer community. Together we are driving progress in detection, diagnosis, treatment and care.
To meet the needs of people affected by pancreatic cancer now and in the future, we’re expanding our supporter community, investing in enhancing our supporter relationships and trialling new initiatives.
Team Scotland volunteer Katie with Humza Yousaf at the Scottish Parliament in November 2022
## **Expanding the pancreatic cancer community**
Our **incredible volunteers’** time and experience is vital in placing people affected by pancreatic cancer at the centre of everything we do, from shaping our services to informing our research, participating in our campaigns helping at our events and raising awareness in their communities. During 2022/23, we dramatically increased our cadre of volunteers to 4,642, which will boost our reach and impact.
For example, our **Team Scotland volunteers** raised awareness of pancreatic cancer and its symptoms locally and in the Scottish Parliament. They also shared their experiences to call for faster diagnosis and pancreatic cancer clinical nurse specialists.
31
30
Goal 04
**----- Start of picture text -----**
Annual Report and Financial Statements for the year ended 31st March 2023
**----- End of picture text -----**
We were delighted to **reach more people online,** with over 2.1 million visits to our website in 2022/23. To help us take on pancreatic cancer together, we strive to **understand exactly what our supporters want from us.** And we endeavour to ensure that all our communications with supporters are personalised, efficient and secure.
We support people throughout their entire journey with us, from organising funeral donations and gifts in memory to providing tips and advice on fundraising and the motivation and expertise to get them over the finish line.
## **Increasing awareness of pancreatic cancer and our work**
Our Lost Voices **campaign** honoured everyone who has died too soon from pancreatic cancer, including Alan Rickman. Truly Madly Deeply cast members joined us for a screening of the iconic film in which Alan starred. Bill Patterson, Deborah Findlay and Michael Maloney kindly shared their memories of working on the film at an event hosted by our ambassador BBC journalist Ben Mundy. We’re proud that this campaign won Charity Communications Campaign of the Year at the Third Sector Awards.
**----- Start of picture text -----**
[Bill Patterson, Deborah Findlay ]
and Michael Maloney at the
Truly Madly Deeply screening
**----- End of picture text -----**
## **“**
I cannot put into words how fabulous the marathon was. I wanted to say a huge thank you to the team and volunteers who made the whole experience incredible from start to finish. I was running in memory of my mum, who we sadly lost to this awful and aggressive disease at Christmas last year. I managed to raise just over £13k and I hope her memory helps to transform the future! Was so great seeing all the PCUK runners in their tops and supporting each other.
## **Rosie, London Marathon participant**
**----- Start of picture text -----**
[At the Third Sector Awards accepting ]
our award for the Charity Campaign
of the Year Award
**----- End of picture text -----**
33
32
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 04
**----- Start of picture text -----**
Barbara Flynn at our
Christmas Carol Concert
**----- End of picture text -----**
Our **Christmas Carol Concert** was a wonderful and moving opportunity to gather supporters together.
We **reached 13.5 million people digitally via social media, our website and email** during the month – 300% more than last year.
It was made extra special with festive readings by our celebrity ambassadors and supporters Olivia Williams, Barbara Flynn, Cariad Lloyd, Nicholas Owen and Jenny Oldfield.
Almost **200 landmarks and homes were lit up in purple on World Pancreatic Cancer Day** to raise vital awareness, including Battersea Power Station, Belfast City Hall, Edinburgh City Chambers and Carmarthen County Hall. Ruby Wax supported our annual **St Pancras takeover of London’s Kings Cross** , by voicing awareness announcements in the station and through her social channels.
During **Pancreatic Cancer Awareness Month** (November), we asked people to raise vital awareness and funds for pancreatic cancer. Supporters across the UK shared information on symptoms, told their stories in Parliament and the media, and raised a fantastic £352,711 from our Walk 30k in November challenge.
## **Building more sustainable income**
To ensure we can support people affected by pancreatic cancer now, and future research breakthroughs, we continually diversify our fundraising activities while building on successful initiatives.
Our new in memory Facebook event enabled people to come together to light a candle, share memories and raise money in memory of someone they have lost to pancreatic cancer.
During the year we were notified of generous pledges in people’s Wills, notably during Remember a Charity week. Legacy giving is a vital part of our income and we appreciate every gift, whatever its size
After Angela was diagnosed with pancreatic cancer in August 2020, she used our online Free Will Service to ensure her loved ones and the causes she cared about were provided for. Angela chose to leave a special message to our nurses, together with a gift in her Will to us, in the hope that, one day, research into pancreatic cancer will make the pain and difficulty she endured a thing of the past.
**“**
- Thank you for the wealth of support you gave me, especially Lynne and Rachel. You were always there for me, like guardian angels.”
## **Angela**
35
34
Annual Report and Financial Statements for the year ended 31st March 2023
Goal 04
Some of our scientists joined Amir Khan, Ainsley Harriott and our ambassadors Olivia Williams, Barbara Flynn and Sabrina Gidda in a powerful campaign video which helped to raise awareness of the need for investment into early detection research.
Every pound donated through our **Double Donations campaign** was generously matched by the Freddie Green & Family Charitable Foundation, in memory of Jo Green who died of pancreatic cancer in 2021. It was our most successful individual giving campaign ever raising £244,000 which was doubled to £488,000.
Our **Weekly Lottery** went from strength to strength, with more players than ever. And our **Winter Appeal** , featuring the story of our supporter Maureen and her son Piers, was hugely successful.
**----- Start of picture text -----**
Maureen, Piers and his children
**----- End of picture text -----**
Our intrepid supporters took part in various active fundraising challenges and adventures last year. These included our **Jog 28 virtual Facebook challenge** and **fundraising skydives.** Participants also took on **RideLondon-Essex 100** including Emmerdale actor and longstanding supporter Tony Audenshaw and his ‘Wheelpackers’ team. Tony spoke movingly about losing his wife Ruth to pancreatic cancer on ITV’s This Morning, underlining the importance of our research and Support Line.
Through our **Unite, Diagnose, Save Lives campaign,** our supporters demanded earlier diagnosis to improve outcomes for people who have pancreatic cancer. An impressive 61,144 people actively supported the campaign, and hundreds made one-off or regular gifts to support our work.
And of the tens of thousands of people, who signed our **No Time To Wait** petition hundreds also gave to us financially.
## **Thank you!**
Thank you to everyone who supported our work in 2022/23. We particularly want to thank:
- The Freddie Green & Family Charitable Foundation for their significant commitment to our research programme in memory of Jo Green
- Organisations from across the UK that raised vital funds and awareness of pancreatic cancer, including The Real Greek, Fugro, Scotmid, Meg Events and Capstone
- The Ellis family, for their incredible generosity and support of our research programme in memory of Lesley
- Our industry partners Bristol-Myers Squibb, MSD, Astellas, Viatris and Oncosil
- Our ambassadors and Development Fund Board members: Robin Phillips, Deborah and Robert Ware, Gary and Penny Chapman, Jonathan Harper and his colleagues at Spencer Stuart, Remony and Grahame Millwater, David Lewis, Keith Porritt, Brigitte Frankel, Alison Mackintosh and Marion Pughe-Morgan
- All our wonderful philanthropists
- The charitable trusts and foundations that helped us expand our research programmes and support services, notably the Oak Foundation for its long-term support of our research and data intelligence teams, The Chellaram Foundation and the Inman Charity
37
36
Annual Report and Financial Statements for the year ended 31st March 2023
Looking ahead
Looking ahead: Finding breakthroughs. Giving hope. Saving lives.
**We will drive earlier and faster diagnosis** so everyone can be diagnosed early enough for treatment
## **Pancreatic cancer is still tough to detect, treat and survive. But in the last five years we’ve seen more progress than in the previous 50 years.**
In the next five years, we will build on this momentum. We aim to double pancreatic cancer survival rates in the UK by transforming how we diagnose, treat and care for people with this disease.
## Based on insights from our stakeholders, our **2023–28 strategy has four objectives.**
To achieve these ambitions, we will double our annual income, double our reach and will double down on making sure we’re as innovative, impactful and cost-effective as possible.
But we can’t make the change that is needed without more supporters and advocates. We hope that you will join us to bring about the transformation in survival rates that we dream of to achieve our vision – for everyone with pancreatic cancer to live long and well.
Sadly, by the time most people are diagnosed with pancreatic cancer, it’s already at a very advanced stage. If we can drive earlier and faster diagnosis, more people will have their cancer detected at a stage where they can have treatment to save, or extend, their life.
## **Between 2023 and 2028 we will:**
- drive forward scientific research into early detection by investing more than ever before
- give health professionals the tools they need to spot patients’ symptoms earlier
- raise awareness of the signs and symptoms among the public
- monitor people at higher risk.
## **So that:**
- more people will be diagnosed sooner – at stage 1 and 2 rather than stage 3 or 4
- fewer people will be diagnosed in emergency settings such as A&E
- more people will be referred for life-saving or lifeextending treatment
- more people will survive.
39
38
Annual Report and Financial Statements for the year ended 31st March 2023
Looking ahead
**----- Start of picture text -----**
2.
**----- End of picture text -----**
## **We will accelerate treatment breakthroughs** so that people can benefit from better and more effective treatments
Pancreatic cancer is so complex that it has been hard to find effective treatments, so options are often limited. If we can accelerate treatment breakthroughs, we will give people with pancreatic cancer better and more effective treatments, so they can have a longer, and better quality of, life.
## **Between 2023 and 2028 we will:**
- campaign for more research investment from government and other bodies
- transform the scale of our investment into research dedicated to developing trials and treatments
- ensure the research community has the funding and tools they need to find breakthroughs
- improve how people are supported through their experience.
## **So that:**
- more people will be able to access high-quality treatment and the care they need
- fewer people will see their cancer come back after treatment
- people with pancreatic cancer will have a better quality of life
- more people will survive.
**----- Start of picture text -----**
3.
**----- End of picture text -----**
## **We will ensure high-quality treatment and care is available everywhere**
## so that everyone can access good care, wherever they live
Pancreatic cancer is tough to detect – but even once it’s spotted, people can go on to face potentially huge obstacles: from getting their diagnosis, treatment and care – to having a better quality of life, and surviving. We know people with pancreatic cancer face a postcode lottery of care and we’re determined to change this.
## **Between 2023 and 2028 we will:**
- achieve a consensus on what equals ‘best’ and make sure it benefits everyone
- inspire more people to join us to keep pancreatic cancer care high on the agenda
- provide training for health and care professionals to improve practice
- use data to help inform better care and support.
## **So that:**
- more people will have access to high-quality treatment and personalised care, regardless of where they live
- more people will be able to participate in clinical trials if they choose to
- more people will remain well enough to embark on and complete active treatment
- people with pancreatic cancer will have a better quality of life
- more people will survive.
41
40
Annual Report and Financial Statements for the year ended 31st March 2023
Looking ahead
**----- Start of picture text -----**
4.
**----- End of picture text -----**
**We will improve quality of life today** so that everyone is supported, empowered, and better able to manage their symptoms
Pancreatic cancer affects so many aspects of people’s lives – both physical and emotional. If we can support people, helping them to reduce the impact of their symptoms and take control of their experience and treatment, we can improve their, and their loved ones’, quality of life today.
## **Between 2023 and 2028 we will:**
- develop a wider range of services, tools and information to make the support we offer more diverse and accessible
- give more opportunities for personalised and peer support
- collect data via our Medli app to inform improvements in care.
## **So that:**
- people with pancreatic cancer will be aware of and able to access high-quality treatment and care
- people will be better informed, better able to manage their symptoms, and better placed to feel more in control
- more people will feel well enough – and well-supported enough – to complete treatment
- people with pancreatic cancer will have a better quality of life.
43
Structure, Governance and Management
Annual Report and Financial Statements for the year ended 31st March 2023
## Structure, Governance and Management
## **Organisational structure**
2018 this assessment has been based on standards informed by the Nolan Principles of Public Life: selflessness, integrity, objectivity, accountability, openness, honesty and leadership and the Charity Governance Code.
The organisation is a charitable company limited by guarantee, incorporated on 19th December 2005 and registered as a charity on 13th January 2006. The company was established under a Memorandum of Association which established the powers and objects of the charitable company and is governed under its Articles of Association of the same date.
The charity has a Scientific Advisory Board (SAB) that helps direct the work of the charity by providing expert advice to the Chief Executive Officer (CEO) and Trustees on:
## **Related Parties**
- The charity’s research strategy and grant giving programme
A wholly owned trading subsidiary was opened on 31st March 2022, Pancreatic Cancer UK Trading Limited. The trading subsidiary is used to manage retail activity, licensing and future trading activity. The directors of the company are also charity trustees and under the company’s Articles are empowered to manage the business of the company. An independent director has been appointed.
- External referees for grant applications (‘peer reviews’)
- Assessment of and final recommendations for grant applications
The SAB also provides advice and support for the charity on reporting and dissemination of research results.
The Board comprises 10 Trustees, who are also directors of the company. The Trustees who served during the period and to the date of signing this report are listed on page 81. The Board meets at least four times a year. The Trustee Board takes overall responsibility for ensuring that the financial, legal and contractual responsibilities of the charity are met, and that there are satisfactory systems of financial and other controls. All decisions are currently ratified by the Board.
The day-to-day management of the charity is delegated to the CEO who works with the Senior Management Team; Anna Jewell, Director of Services Research and Information, Sue Collins, Director of Fundraising & Marketing, Sherie Holding, Director of People and Culture, Joan Prendergast, Director of Finance, Planning and Resources, and Julie Roberts, Director of Transformation Programmes along with a team of staff to fulfil the charity’s objectives.
Trustees periodically undertake a board effectiveness self-assessment. Since
A number of Trustees, including the Chair and Treasurer, are appointed to the Finance Risk and Planning Committee which reviews the charity’s financial and audit reports, budgets and plans on a quarterly basis ahead of making recommendations to the full Board. This committee is also responsible for ensuring the charity’s risks are effectively managed and that the charity is compliant with all relevant regulations.
A People and Culture Committee is in place to give oversight to policies and procedures relating to our people – staff, volunteers and involvement participants.
The Trustees also have a Remuneration Sub-committee which annually assesses staff salaries, including key management personnel against the charity’s approved Pay Policy, which was last updated in November 2021. All salaries have been benchmarked and are monitored to ensure they are in line with the rest of the charity sector.
## **Trustee induction and development**
All new full and co-opted Trustees are inducted by the Chief Executive and the current Board in line with the charity’s induction policy. All Trustees have a periodic one-to-one review with the Chair at which specific development or training needs are identified. All Trustees are encouraged to attend relevant conferences and to request any support relevant to their position in the organisation. Over the course of 2022/23 Trustees have continued to actively support of the Senior Leadership Team.
## **Risk statement**
The Trustees have considered the major risks to which the charity may be exposed.
The principal risks that we face in the charity are:
- a) that our comments or opinions might be understood to be offering medical or other advice which we are not qualified to provide. The charity notes that it does not and cannot offer “advice” and therefore takes extreme care with the language used in its communications, most especially on its website to avoid any possible misunderstanding in this regard.
- b) that we might choose to allocate funds to programmes of work that are unlikely to succeed or are, at worst, fraudulent. The charity has established a Scientific Advisory Board whose advice will always be sought on significant research expenditure.
- c) that we may not meet our annual income targets and not be able to resource our planned activities. To this end the Charity develops an annual budget in support of its operational plan which is approved by Trustees. This forms the basis for financial monitoring. Management accounts and financial forecasts are reviewed monthly by the Treasurer and Chair, and accounts are reviewed by the Finance Risk and Planning Committee ahead of the full Board of Trustees on a quarterly basis. The Charity also holds sufficient reserves to off-set income risks.
- d) that we might lose key members of staff. Staff contracts ensure sufficient notice periods to allow recruitment and handover.
- e) that the impact on the economy from the cost of living increase and the global economic impact of the conflict inUkraine will materially reduce the charity’s annual income from 2023 onwards, and increase costs. The charity’s budgeting and monitoring process in (c) above mitigates this risk, together with the charity’s level of reserves.
45
44
Structure, Governance and Management
Annual Report and Financial Statements for the year ended 31st March 2023
f) Continuous changes in working practice may adversely impact on staff health and wellbeing. Staff wellbeing and working preferences are a major consideration in environment planning, with the aim of providing a working environment and approach that is both supportive and productive.
## **Charity’s aim**
Our vision for the future is a world where everyone with pancreatic cancer survives to live long and well. To do this, we lead the fight against pancreatic cancer. Pancreatic cancer is tough to diagnose, tough to treat, tough to research and tough to survive, and for too long this disease has been sidelined. We want to make sure that everyone affected by it gets the help they need.
The charity has developed a Risk Management Framework which indicates the risk appetite and risk tolerance across a range of categories.
The charity also has a Risk which has been approved by the Board and is reviewed every three months. New or emerging risks are escalated to the Board as they are identified in the intervening periods.
· We provide expert, personalised support and information via our Support Line and through a range of publications
· We fund innovative research to find the breakthroughs that will change how we understand, diagnose and treat pancreatic cancer
## **Public benefit**
The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Commission in determining the activities undertaken by the charity. The Trustees’ Report section on Objectives, Activities and Performance on pages 8 to 37 sets out how the charity addresses the public benefit requirement, and this is also explicit in the Charity’s Aim set out below.
· We campaign for change; for better care, treatment and research, and for pancreatic cancer to have the recognition it needs.
In this way we fulfil the charitable objects which are for the relief of those who are affected by pancreatic cancer including patients, their families and carers, in particular by providing direct support and information to those affected.
## **“**
All Trustees have an annual one-to-one review with the Chair at which specific development or training needs are identified. All Trustees are encouraged to attend relevant conferences and to request any support relevant to their position in the organisation.
## **“**
We review all of our fundraising campaigns to ensure they fully comply with the code
## **Our approach to fundraising**
As a supporter-focused charity, we recognise that the progress we make for people affected by pancreatic cancer would not be possible without the passion and generosity of our supporters. That is why our Fundraising Promise remains at the heart of how we fundraise. If you choose to support us, you can be certain that we will:
- never put you under pressure to donate
- be clear with you about our charity’s aims and objectives
- respect your choices to opt in or out of our fundraising communications
- never share or sell your details to other charities or third parties for their own marketing purposes
- comply with all relevant data protection laws
- listen and learn – you can provide feedback about our fundraising at any time
- communicate with you in a way that suits you best
Read our Fundraising Promise in full. We are registered with the regulatory body for fundraising in the UK, the Fundraising Regulator, and pay an annual levy to support its work. We adhere to the standards outlined in the regulator’s Code of Fundraising Practice (the code). We fundraise in diverse ways to tell as many people as possible about our work. Our fundraising activities currently include direct mail, email direct marketing, sponsored running, challenge and community-led events, and cash collections. We also host fundraising gala dinners and other social activities. We regularly review our fundraising campaigns to ensure they fully comply with the code, do not place an unreasonable intrusion on anyone’s privacy or put undue pressure on them to donate. Our fundraising activities are also closely monitored by the Finance, Risk and Planning Committee, which reports to our Board of Trustees.
We work with carefully selected partners to deliver some fundraising activities. Before doing so, we ensure they are fully compliant with the code and all applicable laws, including those on data protection. We also monitor their activities through regular quality assurance checks to ensure they treat our supporters fairly and have the necessary safeguards in place to protect vulnerable people.
We encourage and learn from feedback from our supporters. In accordance with disclosure guidance from the Fundraising Regulator, we received 32 complaints relating to our fundraising activity in 2022/23, (2021/22: 28). All complaints are reviewed carefully and where appropriate, action is taken to resolve. The increase in complaints in the last year was the result of increased activity.
47
46
Structure, Governance and Management
Annual Report and Financial Statements for the year ended 31st March 2023
## **Our people**
Our organisation continues its steady trajectory of growth, ensuring that we are bringing in the right skills at the right level to grow organisation capability and also replace skills and experience lost through attrition. Attrition can provide an opportunity for fresh talent to join the organisation, however the leanness of our structure means that when vacancies remain open for too long we can see an impact on our people and our ability to remain effective.
As with all organisations the impact of the cost-of-living crisis has been at the forefront of our minds and making sure that our employees have felt supported during this time has been a priority. To help combat this we provided a cost-of-living supplement in October, a pay increase in April, and a number of support tools for all staff. We continue to keep a watching brief on this situation.
Our headcount was 94 as of 31 March 2023, (78 as at 31 March 2022), with 1 member of staff made redundant during the year following a restructure.
We are a high performing organisation and have delivered some truly astounding work through our people’s efforts across the organisation. This gives us the confidence to have a bold and ambitious strategy as we believe that our people have the capability to rise and grow with the organisation. However, we also recognise that we will need to either develop new skills within our existing staff or bring new skills into the organisation to meet our objectives.
This year we are focussing on sustaining our growth as we bring more people into
our organisation, and retaining our culture of taking on big challenges. This will require us to look at what works and what needs to work better in the future and transforming the way that we work as we evolve. The risk of being a growing organisation is that we grow apart and lose our ability to work in close quarters and develop siloed practices that are detrimental to the cohesiveness of the organisation. It is clear that we need to be focussed on ensuring that we do not allow this to happen, and that we are keeping a close eye on workloads and that our people do not feel unduly pressured to deliver above and beyond what is reasonable.
We know that our employees are incredibly motivated about our cause, we still need to treat them fairly and compensate them accordingly for their efforts and provide other ways to keep them feeling invested by the organisation. We continue to monitor pay and benefits equity and we need to continue with our efforts to create a better working environment for our people, looking in particular towards wellbeing, mental health, career development and progression and non-financial benefits.
2022/2023 was our first year of working in a more defined hybrid approach and our staff seem to be adjusting to this well and feeling the benefits of this more flexible approach. It has also helped with our recruitment. We have also adopted a more flexible approach to working patterns, which we will need to review the impact to productivity, collaboration and organisation dynamics over the course of this next year.
The recruitment continues to change and the needs of people along with this, especially within the younger generation who are asking for more and different things out of work and the organisations that they want to work for, so we have to keep abreast of these changes and reflect this in the way we recruit and also what we offer as an
Employer Brand. As such we continue our commitment to improving our approach to inclusion and diversity and ensuring we have a supportive and nurturing environment where people can produce their best work.
We further recognise that our people managers are integral to ensuring that our people perform well and are supported to continue to do so, so we will be looking how we ensure that all of our managers are equipped to deal with the changing requirements of managing people in this fluid and changeable times, and that they (managers) get the support that they also need.
Our people are not just paid staff, but also volunteers and those who support us through various different activities such as campaigning, lay reviewers, advisory panels, supporting others affected by pancreatic cancer. It is equally important that we recognise and value the contribution made this group of people and provide opportunities for those who want to support us in other ways aside from raising funds. We are looking at ways to grow this population and provide them with the appropriate level of engagement and opportunities for us to incorporate the voices of lived experience of being impacted by pancreatic cancer across the organisation, in a supportive, sensitive and mindful way.
49
48
Structure, Governance and Management
Annual Report and Financial Statements for the year ended 31st March 2023
## Financial Review 2022/2023
Total income for the year was 11,497,561 (2021/22: £9,347,560), a record year for the charity. Despite the significant challenges that impacted the sector post-pandemic, including the cost of living crisis, our fundraising teams were able to consolidate the move to digital and virtual fundraising activities as well as successfully implement the return of face-to-face events and community activities.
Even though we have increased our funds, we nevertheless still need to raise more income to substantially grow our future funding for pancreatic cancer research and invest in building pancreatic cancer data and digital resources, and to improve care and treatment of this terrible disease. Costs of generating income were 4,026,830 for the year (2021/22: £3,379,988).
£1,801,677) and paid £749,711 (2021/22 £949,596) in cash in respect of grant awards made in 2021/22 and earlier. The charity has ongoing grant funding commitments of £3,666,014 shown as a creditor on our balance sheet and has designated funds to support the new research strategy which sees considerable investment in research over the next five years.
The increase in cost is the result of return of face to face events as well as two London marathon events during the year. In addition, we have been continuing to invest in building capacity and efficiency for longer term income growth and sustainability. These costs represented 35% of our total income for the year and 36% of our total expenditure.
Expenditure on research in 2022/23 included costs of managing our research programme, including working with research institutions and other funders, gathering data, promoting grant investment opportunities, working with our Scientific Advisory Board, and coordinating reviews ahead of making grant awards for following years. Proposals for new grants undergo a robust process of review before being awarded, which can take over a year, and grant awards normally have a duration of 1-3 years.
## **Research grants**
## **Our services and support costs**
In addition to providing vital research funding, we have also continued to invest in increasing the impact and effectiveness of our support services. We have launched our Medli app to provide those affected by pancreatic cancer with symptom management tools, medication management tools, as well as access to pancreatic cancer trials information.
We have continued to develop the support information we provide and the continued use of digital platforms continues to increase the services we can provide for patients and carers. During the year, we spent £2,014,623 (2021/22 £1,644,125) on delivering our vital support and information services.
## **Campaigning and awareness**
We continue to increase our campaigning and profile-raising work, with expenditure during the year of £1,842,104 (2021/22 £1,497,469).
## **Reserves**
Total reserves grew by £458,230 during the year from £6,305,125 at the start of the year to £6,763,335 at 31 March 2023. Reserves are split between restricted funds, those given for specific purposes, designated funds, those allocated by Trustees to underpin or invest in specific areas, and general funds, which are split into operating contingency and unrestricted reserves. A breakdown funds is given below.
## **Restricted funds**
At 31 March 2023 £935,818 was held in restricted funds (2021/22 £75,918), £855,330 of which is restricted to research projects as per donors wishes. The increase in restricted funds is a result of the increase in research projects committed to during the year, and subsequent donor support.
## **Designated funds**
At 31 March 2023 £3,831,333 was held in designated funds (2021/22 £3,904,258). £3,294,332 was held for research as at 31 March 2023 (2021/22 £3,204,258), with £1,409,926 having been spent during the year and a further £1,500,000 designated by Trustees. Trustees have also designated funds to support infrastructure development. £537,000 was held for infrastructure support as at 31 March 2023 (2021/22 £700,000), with £163,000 having been spent during the year.
## **General funds**
The Trustees undertook a review of the charity’s reserves policy during the year and have determined a level of free reserves to be held sufficient to provide an operating cost contingency of £1,450,000 (2021/22 £1,192,000) which would fund three months’ salaries, 12 months’ rent and approximately one month of all other costs. In addition, £357,699 (2021/22 £365,264) was held in fixed assets, and a further £188,505 (2021/22 £767,685) is held as a free reserve to underwrite risks in income generation.
New grants are charged to the accounts in full at the date they are awarded, which is when the charity is committed to payment for the duration of the grant. During 2022/23, the charity awarded new grants amounting to £2,211,214 (2021/22
51
50
Structure, Governance and Management
Annual Report and Financial Statements for the year ended 31st March 2023
## Utilisation of the charity’s reserves at 31st March 2023 is summarised below:
||**£**|
|---|---|
|Restricted Funds|**£935,818**|
|Designated funds|£3,831,333|
|General funds||
|Operating contingency|£1,450,000|
|Fixed Assets|£357,699|
|Other|188,505|
|**Total Reserves**|**6,763,355**|
## **Responsibilities of the Trustees**
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
The Trustees, who are also directors of Pancreatic Cancer UK for the purposes of company law, are responsible for preparing the Trustees’ Report, incorporating the strategic report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
Company and charity law requires the Trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charitable company including income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.
The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies
Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charity Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
The Trustees refer to the Charity Commission’s guidance on public benefit when reviewing the charities aims and objectives and planning for the future.
## **Provision of information to auditors**
Each of the persons who are Trustees at the time when this Trustees’ Report, incorporating strategic report is approved has confirmed that:
- there is no relevant audit information of which the company’s auditors are unaware, and
**Signed** on behalf of the Board of Trustees by:
**Eleanor Phillips,** Chair of Board of Trustees Dated: 3 October 2023
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.
53
52
Annual Report and Financial Statements for the year ended 31st March 2023
Independent Auditor’s Report
## Independent Auditor’s Report
to the members and trustees of Pancreatic Cancer UK for the year ended 31st March 2023
## **Opinion**
We have audited the financial statements of Pancreatic Cancer UK for the year ended 31 March 2023 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charity Balance Sheet, the Consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.
## **Basis for opinion**
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
In our opinion, the financial statements:
- give a true and fair view of the state of the group’s and of the parent charitable company’s affairs as at 31 March 2023 and of the group’s and parent charitable company’s net movement in funds, including the income and expenditure, for the year then ended;
## **Conclusions relating to going concern**
In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.
## **Other information**
The trustees are responsible for the other information. The other information comprises the information included in the Trustees’ Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other
information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
## **Opinions on other matters prescribed by the Companies Act 2006**
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Trustees’ Annual Report (which includes the strategic report and the directors’ report prepared for the purposes of company law) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors’ report included within the Trustees’ Annual Report have been prepared in accordance with applicable legal requirements.
55
54
Annual Report and Financial Statements for the year ended 31st March 2023
Independent Auditor’s Report
## **Matters on which we are required to report by exception**
In the light of the knowledge and understanding of the group and the parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees’ Annual Report which incorporates the strategic report and the directors’ report).
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 require us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent charitable company; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees’ remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
## **Responsibilities of trustees for the financial statements**
As explained more fully in the trustees’ responsibilities statement set out on pages 52 to 53, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine
is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the trustees are responsible for assessing the group’s and the parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.
## **Auditor’s responsibilities for the audit of the financial statements**
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
Based on our understanding of the group and the environment in which it operates, we identified that the principal risks of non-compliance with
laws and regulations related to Charity and Company law, and we considered the extent to which noncompliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006, the Charities Act 2011, fundraising regulations and payroll taxes.
We evaluated management’s incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to income recognition. Audit procedures performed by the engagement team included:
- Inspecting correspondence with regulators and tax authorities;
- Discussions with management including consideration of known or suspected instances of noncompliance with laws and regulation and fraud;
- Review of minutes of meetings;
- Evaluating management’s controls designed to prevent and detect irregularities;
- Identifying and testing journals, in particular journal entries posted with unusual account combinations, postings by unusual users or with unusual descriptions; and
- Challenging assumptions and judgements made by management in their critical accounting estimates, in particular donation and legacy recognition, recognition of grant expenditure and provisions for bad and/or doubtful debts.
Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of noncompliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/ auditorsresponsibilities. This description forms part of our auditor’s report.
## **Use of our report**
This report is made solely to the charitable company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company’s members those matters we are required to state to them in an Auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
**Vikram Sandhu,** Senior Statutory Auditor Date: 17 October 2023
For and on behalf of Haysmacintyre LLP, Statutory Auditor 10 Queen Street Place, London, EC4R 1AG
57
56
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## Financial statements
## Financial Statements
## Consolidated statement of financial activities **For the year ended 31st March 2023**
**----- Start of picture text -----**
UNRESTRICTED RESTRICTED TOTAL TOTAL
FUNDS 2023 FUNDS 2023 2023 2022
NOTES £ £ £ £
IINCOME FROM:
Donations and Legacies 2 9,033,813 2,102,210 11,136,023 8,899,524
Other trading activities:
Merchandise income 353,271 - 353,271 446,341
Investments 8,267 - 8,267 1,695
Total Income 9,395,351 2,102,210 11,497,561 9,347,560
EXPENDITURE ON:
Raising funds 3b 4,026,830 - 4,026,830 3,379,988
Charitable activities 2b
Information and support 1,937,418 77,205 2,014,623 1,644,125
Campaigning and awareness 1,791,607 50,497 1,842,104 1,497,469
Research 2,354,485 801,289 3,155,774 2,564,503
Total Expenditure 3 10,110,340 928,991 11,039,331 9,086,085
Net (expenditure) income (714,989) 1,173,219 458,230 261,474
Funds opening balance 6,229,207 75,918 6,305,125 6,043,650
Transfers between funds 313,319 (313,319) - -
Funds closing balance 12 5,827,537 935,818 6,763,355 6,305,124
**----- End of picture text -----**
All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above.
The notes on pages 61 to 81 form part of these financial statements. Full comparative figures for the year to 31 March 2022 are shown in note 16.
## Company Number 05658041 Balance Sheet **As at 31st March 2023**
**----- Start of picture text -----**
CONSOLIDATED CHARITY
2023 2022 2023 2022
NOTES £ £ £ £
IFIXED ASSETS
Tangible assets 7 357,699 365,264 357,699 365,264
Investments 60,000 - 60,000 -
CURRENT ASSETS
Debtors 9 1,098,896 2,049,972 1,220,184 2,049,972
Stock 8 98,461 133,292 - 133,291
Cash and cash equivalents 9,811,875 6,605,673 9,708,526 6,605,672
11,009,232 8,788,937 10,928,710 8,788,935
CREDITORS: amounts falling
10 (2,835,550) (1,499,335) (2,740,437) (1,499,335)
due within one year
Net current assets 8,173,682 7,289,602 8,188,273 7,289,601
CREDITORS: amounts falling
10 (1,828,026) (1,349,741) (1,828,026) (1,349,741)
due after one year
NET ASSETS 6,763,355 6,305,125 6,777,946 6,305,124
FUNDS
Unrestricted funds
General funds 12 1,996,204 2,324,949 2,010,795 2,324,948
Designated funds 12 3,831,333 3,904,258 3,831,333 3,904,258
Restricted funds 12 935,818 75,918 935,818 75,918
TOTAL FUNDS 6,763,355 6,305,125 6 , 777 , 9 4 6 6,305,124
**----- End of picture text -----**
Approved by the Trustees and authorised for their issue on 3 October 2023 and signed on their behalf by:
**Eleanor Phillips** Chair of Trustees
The notes on pages 61 to 81 form part of these financial statements
59
58
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## Consolidated statement of cash flows
## **As at 31st March 2023**
|**As at 31st March 2023**|**As at 31st March 2023**|
|---|---|
|**NOTES**
**2023**
**£**
**2022**
**£**||
|||
|**Cash used in operating activities**
A
**3,344,070**|**762,591**|
|**Cash fows from investing activities**||
|Interest income
8,267
1,695||
|Purchase of investments
(60,000)
0||
|Disposal of tangible fxed assets
4,092|4,081|
|Purchase of tangible assets
(90,227)|(40,950)|
|**Cash used in investing activities**
**(137,869)**
**(35,174)**||
|**(Decrease) increase in cash and cash equivalents in the year**
**3,206,202**
**727,417**||
|Cash and cash equivalents at the beginning of the year
6,605,673
5,878,256||
|**Total cash and cash equivalents at the end of the year**
**9,811,875**|**6,605,673**|
## **A. Reconciliation of net movement in funds to net cash inflow from operating activities**
|**2023**
**£**
**2022**
**£**|**2023**
**£**
**2022**
**£**|
|---|---|
|**Net income / (expenditure)**
458,230
261,474||
|Depreciation charge
93,700
82,785||
|Investment income
(8,267)|(1,695)|
|(Increase) decrease in stock
34,831|(133,291)|
|(Increase) decrease in debtors
951,076|(438,145)|
|(Decrease) increase in creditors
1,814,500|991,463|
|**Net cash used in operating activities**
**3,344,070**|**762,591**|
## **B. Analysis of changes in cash and cash equivalents**
|**AT 01-APR**
**2022**
**£**
**CASHFLOWS**
**£**
**AT 31-MAR**
**2023**
**£**|**AT 01-APR**
**2022**
**£**
**CASHFLOWS**
**£**
**AT 31-MAR**
**2023**
**£**|**AT 01-APR**
**2022**
**£**
**CASHFLOWS**
**£**
**AT 31-MAR**
**2023**
**£**|
|---|---|---|
|Cash and cash equivalents
6,605,673
3,206,202
9,811,875|||
|Deposit accounts
**-**
**-**
**-**|||
|**6,605,673**|**3,206,202**|**9,811,875**|
## Notes to the financial statements
## **As at 31st March 2023**
## 1a. Accounting policies
## **Basis of preparation**
The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (second edition: effective 1 January 2019) - (Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.
Pancreatic Cancer UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).
Preparation of accounts is on a going concern basis.
The trustees consider there are no material uncertainties about the Charity’s ability to continue as a going concern. The review of our financial position, reserves levels and future plans gives Trustees confidence the charity remains a going concern for the foreseeable future.
## **Basis of consolidation**
The consolidated financial statements incorporate the results of Pancreatic Cancer UK (‘the Charity’) and its subsidiary undertaking Pancreatic Cancer UK Trading Limited. No separate Statement of
Financial Activities (SoFA) or Cash Flow Statement has been prepared for the Charity as permitted by Section 408 of the Companies Act 2006 and FRS 102 Section 1.12 (b) respectively. The accounting policies have been consistently applied across the Group from year to year in accordance with FRS 102.
## **Preparation of accounts on a going concern basis**
The trustees consider there are no material uncertainties about the Charity’s ability to continue as a going concern. The review of our financial position, reserves levels and future plans gives Trustees confidence the charity remains a going concern for the foreseeable future.
## **Income**
All income is included in full in the statement of financial activities when the charity is entitled to the income, it is probable that income will be received, and the amount of income receivable can be measured reliably. Third party platforms, such as Just Giving and Virgin Money provide convenient mechanisms for donors to send funds to the charity. All donations from these sources are received net of charges for card transactions, Gift Aid claims (where relevant), agency fees and VAT thereon where charged. These donations are grossed up for accounting purposes with the gross donations including Gift Aid shown as voluntary income and the related card charges, fees and VAT shown as fundraising costs.
61
60
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
Donations are recorded within the charity’s accounts based on the time of processing and dispatch to the charity by the agency rather than the date of the individual donations. All Gift Aid and related fees for donations are accounted contemporaneously with the donations whether or not they have been remitted/charged.
Gift Aid claimable on donations received directly by the Charity are recorded as donation income in the accounting year when the donation is recorded. The outstanding amounts of such Gift Aid are recorded as a debtor until settlement of the claim is completed.
Investment income received from interest on deposits is included in the accounts on an accruals basis. Government Job Retention Scheme grant income represents the total amount claimed from HMRC under the CJRS. The income is accounted for in the period in which the associated salary payments are made to furloughed staff.
## **Expenditure**
Expenditure is recognised in the year in which they apply to. Expenditure includes attributable VAT which cannot be recovered. The costs of generating funds relate to the costs incurred by the charity associated with attracting and processing the donations received as well as merchandising costs.
Charitable activities expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries.
Grants payable are charged to the accounts in full in the year awarded, as the charity is committed to payment for the duration of the grant.
Expenditure is allocated to the particular activity where the cost relates directly to that activity. However, the cost of overall direction and administration of each activity are apportioned based on staff time attributable to each activity.
Governance costs include the costs of governance arrangements which relate to the general running of the charity, including strategic planning for its future development, external audit, any legal advice for the trustees, and all costs of complying with constitutional and statutory requirements, such as the costs of Trustee meetings and of preparing the statutory accounts and satisfying public accountability.
## **Employee benefits**
Short term benefits including holiday pay are recognised as an expense in the period in which the service is received. Termination benefits are accounted for on an accrual basis and in line with FRS 102.
The charity makes pension contributions based on 4-6% of salary to staff personal pensions. The assets of these schemes are held separately from those of the charity in independently administered funds. The pension cost charge represents contributions payable under this arrangement by the charity to the funds. The charity has no liability other than for the payment of those contributions.
## **Financial instruments**
The charitable company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.
## **Fixed assets and depreciation**
Depreciation is provided at rates calculated Depreciation is provided at rates calculated to write off the cost of each asset over its expected useful life. Depreciation is charged on a straight-line basis, with the following expected useful life:
- Computer equipment and software: 5 years
- Office furniture and fittings: 10 years
Depreciation costs are allocated to activities on the basis of the use of the related assets in those activities. Assets are reviewed for impairment if circumstances indicate that their recoverable value may be less than their carrying value.
## **Debtors**
Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.
## **Critical judgements and estimates**
In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. In the view of the Trustees, the recognition of
liabilities for future grant commitments and the split of these between amounts due in less than and more than one year is an area of judgement significant to the accounts. There are no other areas of judgement or estimation that are likely to result in a material adjustment to the accounts in the next financial year.
## **Creditors and provisions**
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.
63
62
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## 1b. Trading subsidiary
The charity opened a wholly owned trading subsidiary Pancreatic Cancer UK Trading Limited on 31st March 2022, with paid up share capital of £1, with a further £20,000 invested during the year as a loan. Pancreatic Cancer UK Trading Limited is incorporated in the UK. The principal activities of the company are commercial activities, namely sales, promotions, mail order and licensing. A summary of its trading results and net assets is shown below. These results are included in the group consolidation. Audited financial statements are filed with the Registrar of Companies.
||**TOTAL**|**TOTAL**|
|---|---|---|
||**2023**|**2022**|
||**£**|**£**|
|**Proft and loss account**|||
|Turnover|325,771|-|
|Cost of sales|(325,978)|**-**|
|**Gross Proft/(Loss)**|**(207)**|**-**|
|Administrative expenses|(14,385)|**-**|
|**Operating proft/(loss)**|**(14,592)**|**-**|
|Interest receivable and similar income|-|**-**|
|**Proft/(loss) before taxation**|**(14,592)**|**-**|
|Taxation|-|**-**|
|**Proft/(loss) for the fnancial year**|**(14,592)**|**-**|
|Distribution|-|**-**|
|**Net movement in Funds**|**(14,592)**|**-**|
|**Balance sheet as at 31 March 2023**|**TOTAL**
**2023**
**£**|**TOTAL**
**2022**
**£**|
|Stock|98,461|-|
|Debtors|90,169|-|
|Cash|103,350|1|
|Current liabilities|(306,571)|-|
|**Net assets**|**(14,591)**|**1**|
|Share capital|1|1|
|Proft/(loss) account|(14,592)|-|
|**Share capital and reserves**|**(14,591)**|**1**|
## 2. Income
|3a. Expenditure
**DIRECT**
**COSTS**
**£**
**GRANTS**
**AWARDED**
**£**
**SUPPORT**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Raising funds**
3,290,156
-
736, 674
4,026,830
3,379,988
**Charitable activities**
Information and support
1,330,422
-
684, 201
2,014, 623
1,644,125
Campaigning & awareness
1,127,699
-
714,405
1,842,104
1,497,469
Research
266,354
2,211,214
678,206
3,155,774
2,564,503
**6,014,631**
**2,211,214**
**2,813,486**
**11,039,331**
**9,086,085**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Total donations and legacies income for the year includes income from:**
Government Job Retention Scheme grants
-
15,687
Gifts in kind
6,120
26,004
Tax recovered
414,662
519,986
**420,782**
**561,677**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Net income for the year is stated after charging:**
Depreciation
93,699
82,786
Statutory audt
15,732
13,680
Tax services
10,947
6,102
Other services
15,252
10,080
Operating leases
203,876
205,305
**339,506**
**317,953**|3a. Expenditure
**DIRECT**
**COSTS**
**£**
**GRANTS**
**AWARDED**
**£**
**SUPPORT**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Raising funds**
3,290,156
-
736, 674
4,026,830
3,379,988
**Charitable activities**
Information and support
1,330,422
-
684, 201
2,014, 623
1,644,125
Campaigning & awareness
1,127,699
-
714,405
1,842,104
1,497,469
Research
266,354
2,211,214
678,206
3,155,774
2,564,503
**6,014,631**
**2,211,214**
**2,813,486**
**11,039,331**
**9,086,085**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Total donations and legacies income for the year includes income from:**
Government Job Retention Scheme grants
-
15,687
Gifts in kind
6,120
26,004
Tax recovered
414,662
519,986
**420,782**
**561,677**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Net income for the year is stated after charging:**
Depreciation
93,699
82,786
Statutory audt
15,732
13,680
Tax services
10,947
6,102
Other services
15,252
10,080
Operating leases
203,876
205,305
**339,506**
**317,953**|3a. Expenditure
**DIRECT**
**COSTS**
**£**
**GRANTS**
**AWARDED**
**£**
**SUPPORT**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Raising funds**
3,290,156
-
736, 674
4,026,830
3,379,988
**Charitable activities**
Information and support
1,330,422
-
684, 201
2,014, 623
1,644,125
Campaigning & awareness
1,127,699
-
714,405
1,842,104
1,497,469
Research
266,354
2,211,214
678,206
3,155,774
2,564,503
**6,014,631**
**2,211,214**
**2,813,486**
**11,039,331**
**9,086,085**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Total donations and legacies income for the year includes income from:**
Government Job Retention Scheme grants
-
15,687
Gifts in kind
6,120
26,004
Tax recovered
414,662
519,986
**420,782**
**561,677**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Net income for the year is stated after charging:**
Depreciation
93,699
82,786
Statutory audt
15,732
13,680
Tax services
10,947
6,102
Other services
15,252
10,080
Operating leases
203,876
205,305
**339,506**
**317,953**|3a. Expenditure
**DIRECT**
**COSTS**
**£**
**GRANTS**
**AWARDED**
**£**
**SUPPORT**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Raising funds**
3,290,156
-
736, 674
4,026,830
3,379,988
**Charitable activities**
Information and support
1,330,422
-
684, 201
2,014, 623
1,644,125
Campaigning & awareness
1,127,699
-
714,405
1,842,104
1,497,469
Research
266,354
2,211,214
678,206
3,155,774
2,564,503
**6,014,631**
**2,211,214**
**2,813,486**
**11,039,331**
**9,086,085**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Total donations and legacies income for the year includes income from:**
Government Job Retention Scheme grants
-
15,687
Gifts in kind
6,120
26,004
Tax recovered
414,662
519,986
**420,782**
**561,677**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Net income for the year is stated after charging:**
Depreciation
93,699
82,786
Statutory audt
15,732
13,680
Tax services
10,947
6,102
Other services
15,252
10,080
Operating leases
203,876
205,305
**339,506**
**317,953**|3a. Expenditure
**DIRECT**
**COSTS**
**£**
**GRANTS**
**AWARDED**
**£**
**SUPPORT**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Raising funds**
3,290,156
-
736, 674
4,026,830
3,379,988
**Charitable activities**
Information and support
1,330,422
-
684, 201
2,014, 623
1,644,125
Campaigning & awareness
1,127,699
-
714,405
1,842,104
1,497,469
Research
266,354
2,211,214
678,206
3,155,774
2,564,503
**6,014,631**
**2,211,214**
**2,813,486**
**11,039,331**
**9,086,085**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Total donations and legacies income for the year includes income from:**
Government Job Retention Scheme grants
-
15,687
Gifts in kind
6,120
26,004
Tax recovered
414,662
519,986
**420,782**
**561,677**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**
**Net income for the year is stated after charging:**
Depreciation
93,699
82,786
Statutory audt
15,732
13,680
Tax services
10,947
6,102
Other services
15,252
10,080
Operating leases
203,876
205,305
**339,506**
**317,953**|
|---|---|---|---|---|
|**6,014,631**|**2,211,214**|**2,813,486**|**11,039,331**|**9,086,085**|
65
64
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## Support Costs
|Support Costs|Support Costs|Support Costs|Support Costs|Support Costs|
|---|---|---|---|---|
|**STAFF**
**COSTS**
**£**
**PREMISES &**
**OFFICE COSTS**
**£**
**OTHER**
**COSTS**
**£**
**TOTAL**
**2023**
**£**
**TOTAL**
**2022**
**£**|||||
||||||
|**Cost of raising funds**
**392,532**
**112,907**
**231,235**
**736,674**
**658,640**|||||
|**Charitable activities**|||||
|Information and support
340,059
112,907
231,235
684,201
608,699|||||
|Campaigning & awareness
370,263
112,907
231,235
714,405
634,114|||||
|Research
334,064
112,907
231,235
678,206
599,381|||||
|**1,436,918**|**451,628**|**924,940**|**2,813,486**|**2,500,834**|
Support costs have been allocated on the basis of staff time spent on each activity. Governance costs of £20,644 (2022: £24,431) are within support costs. See note 4 for further analysis.
## 3b. Cost of Raising Funds
|3b Cost of Raisin Funds|3b Cost of Raisin Funds|3b Cost of Raisin Funds|
|---|---|---|
|**2023**
**£**
**2022**
**£**
. g|||
||||
|Staff costs
1,068,221
857,213|||
|Fundraising events
1,604,563
1,343,226|||
|Merchandise
325,978
313,790|||
|Collection agency fees and charges
291,394
207,119|||
|Support costs (as above)
736,674
658,640|||
||**4,026,830**|**3,379,988**|
## 4. Governance Costs
|4. Governance Costs|4. Governance Costs|4. Governance Costs|
|---|---|---|
|**2023**
**£**
**2022**
**£**|||
||||
|Audit & accountancy fees
15,732
13,680|||
|Trustees expenses and meetings
4,912
10,751|||
||**20,644**|**24,431**|
Governance costs have been allocated to support costs. Three trustees claimed expenses for travel during the year, totalling £1,895.
## 5. Grants payable
|5. Grants payable|5. Grants payable|5. Grants payable|
|---|---|---|
|**2023**
**£**
**2022**
**£**
**Reconciliation of grants payable:**
|||
|Outstanding commitments at 31 March 2022
2,204,511
1,352,430|||
|Grant commitments made in the year
2,211,214
1,801,677|||
|Grants paid during the year
(749,711)
(949,596)|||
|**Outstanding commitments at 31 March 2023**|**3,666,014**|**2,204,511**|
All grants above were made to hospitals, medical schools and other institutions furthering research into pancreatic cancer. There were no grants to individuals in the year to 31 March 2023 (2022: none). Of the outstanding commitments £1,837,988 are due within one year and £1,828,026 after one year.
## 6. Staff costs and numbers
|6. Staff costs and numbers|6. Staff costs and numbers|6. Staff costs and numbers|
|---|---|---|
|**2023**
**£**
**2022**
**£**
**Staff costs were as follows:**|||
|Staff Salaries
3,538,871
3,032,406|||
|Social security costs
400,580
315,932|||
|Pension contributions
290,644
249,719|||
||**4,230,095**|**3,598,057**|
Staff costs set out in the table include redundancy payments of £5,763 (2022: £9,415). The table below sets out the salary bandings (excluding pensions) for employees with salaries over £60k
||**2023**
**NO. OF**
**EMPLOYEES**|**2022**
**NO. OF**
**EMPLOYEES**|
|---|---|---|
|£60k to £70k|8|4|
|£70k to £80k|0|0|
|£80k to £90k|2|1|
|£90k to £100k|1|0|
|£100k to £110k|1|1|
67
66
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## **Key Management remuneration**
The total employee benefits of the key management personnel of the charity was £524,358 (2022: £448,262). The increase being the result of an additional Director post being added in the year.
|**NO.**
**NO.**
**The average number of employees during the year was as follows:**|**NO.**
**NO.**
**The average number of employees during the year was as follows:**|**NO.**
**NO.**
**The average number of employees during the year was as follows:**|
|---|---|---|
|Employees
76
72|||
|Temporary staff
2
6|||
||**78**|**78**|
## 7. Tangible fixed assets
**----- Start of picture text -----**
COMPUTER
OFFICE OFFICE ACCOUNTING EQUIPMENT &
FITTINGS FURNITURE SYSTEM WEBSITE SOFTWARE TOTAL
£ £ £ £ £ £
Cost
At 31 March 2022 222,910 4,803 62,425 138,768 239,565 668,471
- - -
Additions in year 59,143 31,084 90,227
- - - -
Reclassified in year 70,200 (70,200)
- -
Disposals (11,506) (5,655) (6,362) (23,523)
At 31 March 2022 282,053 63,497 56,770 138,768 194,087 735,175
Depreciation
At 31 March 2022 49,890 1,872 25,704 55,160 170,582 303,208
- - - -
Reclassified in year 69,388 (69,388)
Charge for the year 26,614 1,292 12,485 27,754 25,555 93,700
- -
Disposals (10,453) (2,617) (6,362) (19,432)
At 31 March 2023 76,504 62,099 35,572 82,914 120,387 377,476
Net book value
At 31 March 2023 205,549 1,398 21,198 55,854 73,700 357,699
At 31 March 2022 173,021 2,931 36,721 83,608 68,984 365,265
**----- End of picture text -----**
## 8. Stock
|.
**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Goods for resale
98,461
133,291
-
-|.
**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Goods for resale
98,461
133,291
-
-|.
**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Goods for resale
98,461
133,291
-
-|.
**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Goods for resale
98,461
133,291
-
-|.
**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Goods for resale
98,461
133,291
-
-|
|---|---|---|---|---|
||**98,461**|**133,291**|**-**|**-**|
|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Other debtors
120,512
300,691
95,039
300,691
9. Debtors|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Other debtors
120,512
300,691
95,039
300,691
9. Debtors|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Other debtors
120,512
300,691
95,039
300,691
9. Debtors|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Other debtors
120,512
300,691
95,039
300,691
9. Debtors|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Other debtors
120,512
300,691
95,039
300,691
9. Debtors|
|---|---|---|---|---|
|Amounts owed by group undertaking
-
-
211,457
-|||||
|Prepayments and accrued income
978,384
1,749,280
913,688
1,749,280|||||
||**1,098,896**|**2,049,971**|**1,220,184**|**2,049,971**|
Included within accrued income is legacy income of £242,500 (2022: £528,500) being the estimated value of legacies which were notified to the charity prior to the year end.
## 10. Creditors: amounts falling due within one year
|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Accounts payable
376,279
233,072
294,999
233,072|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Accounts payable
376,279
233,072
294,999
233,072|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Accounts payable
376,279
233,072
294,999
233,072|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Accounts payable
376,279
233,072
294,999
233,072|**CONSOLIDATED**
**CHARITY**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**
Accounts payable
376,279
233,072
294,999
233,072|
|---|---|---|---|---|
|Other taxation and social security
115,909
88,914
115,909
88,914|||||
|Deferred Income (see below)
312,500
54,207
312,500
54,207|||||
|Accruals
145,352
247,134
131,520
247,134|||||
|Other creditors
47,522
21,237
47,521
21,237|||||
|Grants payable
1,837,988
854,770
1,837,988
854,770|||||
||**2,835,550**|**1,499,334**|**2,740,437**|**1,499,334**|
|**Amount falling due within one year**|||||
|**Amounts falling due after one year**|||||
|Grants payable|**1,828,026**|**1,349,741**|**1,828,026**|**1,349,741**|
All tangible fixed assets are used to fulfil the charity’s objects.
69
68
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## 10. Creditors: amounts falling due within one year
|
|
|
|
|---|---|---|
|**Analysis of deferred income:**
**2023**
**£**
**2022**
**£**
Balance at 1 April
54,207
-|||
|Amount released to income
54,207
-|||
|Amount deferred in the year
312,500
54,207|||
||**312,500**|**54,207**|
||||
Deferred income relates to funds specified by donors to be spent in the next financial year.
## 11. Analysis of net assets between funds
|**GENERAL**
**FUNDS**
**£**
**RESTRICTED**
**FUNDS**
**£**
**TOTAL**
**FUNDS**
**£**
Tangible fxed assets
357,699
-
357,699|**GENERAL**
**FUNDS**
**£**
**RESTRICTED**
**FUNDS**
**£**
**TOTAL**
**FUNDS**
**£**
Tangible fxed assets
357,699
-
357,699|**GENERAL**
**FUNDS**
**£**
**RESTRICTED**
**FUNDS**
**£**
**TOTAL**
**FUNDS**
**£**
Tangible fxed assets
357,699
-
357,699|
|---|---|---|
|Net current assets
5,469,838|935,818|6,405,656|
|Net assets 31 March 2023
**5,827,537**|**935,818**|**6,763,355**|
## 12. Consolidated funds
|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|
|---|---|---|---|---|
||||||
|**Unrestricted funds:**
**General funds:**|||||
|Operating contingency
1,192,000
-
-
258,000
1,450,000|||||
|Unrestricted reserves
1,132,949
9,395,351
(8,537,415)
(1,444,681)
546,204|||||
|**Total General Funds**
**2,324,949**|**9,395,351**|**(8,537,415)**|**(1,186,681)**|**1,996,204**|
|**Designated Funds:**|||||
|Future research grants,
data and digital development
3,904,258
-
(1,572,925)
1,500,000
3,831,333|||||
|**Total General Funds**
**3,904,258**|**-**|**(1,572,925)**|**1,500,000**|**3,831,333**|
Transfers from restricted to unrestricted funds are to re-imburse payments made from unrestricted funds pending receipt of restricted income.
## **Purpose of designated funds:**
To fund pancreatic cancer research grants over the next three years, together with strategic development of pancreatic cancer data resources and digital services to patients and carers.
71
70
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## 12. Consolidated funds (continued)
|12. Consolidated funds(continued)|12. Consolidated funds(continued)|12. Consolidated funds(continued)|12. Consolidated funds(continued)|12. Consolidated funds(continued)|
|---|---|---|---|---|
|**AT 31 MARCH**
**2022**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2023**
**£**|||||
||||||
|**Restricted funds**
**Research restricted funds**|||||
|Early Diagnosis
-
278,120
-
(278,120)
-|||||
|Europak
-
77,000
(77,000)
-
-|||||
|Future Leaders Fund Cambridge
-
156,250
(132,000)
-
24,250|||||
|Future Leaders Academy Beatson
-
35,000
-
(35,000)
-|||||
|General Research
-
142,328
(142,328)
-
-|||||
|Research Innovation Fund (RIF)
-
120
-
(120)
-|||||
|RIF Chen & Holmes
-
46
-
(46)
-|||||
|RIF2021 Carroll
-
100,000
(90,000)
-
10,000|||||
|RIF2021 Morton
-
85,687
(78,000)
-
7,687|||||
|RIF2021 Sandnandam
-
89,010
(89,010)
-
-|||||
|RIF2021 Tan
-
66,208
(66,208)
-
-|||||
|RIF 2021 Voordeman
-
73,311
(69,000)
-
4,311|||||
|RIF2023 O'Neill
-
2,500
-
-
2,500|||||
|CF2022 Acedo
-
250,000
-
-
250,000|||||
|FF2022 Barbero
-
183,000
(15,743)
-
167,257|||||
|FF2022 Lumeau
-
76,700
(2,000)
-
74,700|||||
|FF2022 Haider
-
62,804
(40,000)
-
22,804|||||
|FF2022 Teeson
-
58,281
-
-
58,281|||||
|FF2022 Williams
-
25,000
-
-
25,000|||||
|Ruth Metcalfe Research Fund
-
33
-
(33)
-|||||
|VAPOR (Breath Test) research project
-
208,540
-
-
208,540|||||
|**Non-research restricted funds**|||||
|Nicki’s Smile
73,421
7,067
-
-
80,488|||||
|Less Survivable Cancers Taskforce
2,497
48,000
(50,497)
-
-|||||
|Support and Information Service
-
67,205
(67,205)
-
-|||||
|Support Service Videos
**-**|10,000|(10,000)|**-**|**-**|
|**Total Restricted Funds**
**75,918**|**2,102,210**|**(928,991)**|**(313,319)**|**935,818**|
|**Total funds**
**6,305,125**|**11,497,561**|**11,039,331**|**-**|**6,763,355**|
## **Purpose of restricted funds:**
## **Early Diagnosis**
Funding from various donors toward all research projects on earlier diagnosis of pancreatic cancer.
## **EUROPAK**
This is funding towards the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC).
## **Future Leaders Fund Cambridge**
Funds for a Pancreatic Cancer Future Leader at the University of Cambridge.
## **Future Leaders Academy Beatson**
Funds for four PHD students to be Pancreatic Cancer Future Leaders at the Beatson Institute’s Future Leaders Academy.
## **General research**
The fund relates to amounts donated towards our research programme but not allocated to a specific project.
## **Research Innovation Fund (RIF)**
The Research Innovation Fund (RIF) was created to spur creative and cutting edge ideas and approaches in pancreatic cancer research including those successful in other areas of cancer research that have justifiable promise for pancreatic cancer. The awards are intended to support pilot work that will put the researchers in a better position to apply for larger grants to take their work to the next stage.
## **RIFYear Name**
Funding for a Research Innovation Fund (RIF) award given in a particular year to named individual.
## **CFYear Name**
Career Fellowship awarded to a named individual in a given year.
## **FFYear Name**
Foundation Fellowship awarded to a named individual in a given year.
## **VAPOR (Breath Test) Research**
Funds towards the VAPOR (Breath Test) research project.
## **Ruth Metcalfe Research Fund**
Funds given in memory of Ruth Metcalfe to be put towards research into pancreatic cancer.
## **Support and Information Service**
The fund relates to amounts donated towards our support and information services work.
## **Nicki’s Smile Fund**
The fund relates to amounts donated by the Nicki’s Smile Appeal and is to be used as recommended and agreed by the Trustees.
## **Less Survivable Cancers Taskforce**
Funds toward our work as part of the Less Survivable Cancers Taskforce. The Less Survivable Cancers Taskforce is made up of six charities and is committed to improving survival rates for people affected by cancer of the brain, lung, liver, stomach, pancreas and oesophagus.
Transfers from restricted funds represent repayment of sums paid out from unrestricted funds ahead of receipt of restricted donations.
Full comparative figures for the year to 31 March 2022 are shown in note 20.
73
72
Annual Report and Financial Statements for the year ended 31st March 2023
**----- Start of picture text -----**
Financial Statements
**----- End of picture text -----**
## 13. Taxation
The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.
## 14. Related party transactions
Aggregate donations of £89,327 (2021: £70,655) were received from the Trustees in the year.
## 15. Operating lease commitments
At the year end, the charity was committed to the following future minimum lease payments in respect of operating leases:respect of operating leases:
|**LAND AND BUILDINGS**
**OFFICE EQUIPMENT**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**|**LAND AND BUILDINGS**
**OFFICE EQUIPMENT**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**|**LAND AND BUILDINGS**
**OFFICE EQUIPMENT**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**|**LAND AND BUILDINGS**
**OFFICE EQUIPMENT**
**2023**
**£**
**2022**
**£**
**2023**
**£**
**2022**
**£**|
|---|---|---|---|
|||||
|In less than one year
202,495
202,495
1,381
1,381||||
|In two to fve years
-
100,415
-
-||||
||**202,495**|**302,910**
**1,381**|**1,381**|
75
74
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## 16. Comparative (Prior Year) Statement of Financial Activities
**----- Start of picture text -----**
UNRESTRICTED RESTRICTED TOTAL
FUNDS FUNDS FUNDS
2022 2022 2022
£ £ £
INCOME FROM:
Donations and legacies 7,794,970 1,104,554 8,899,524
Other trading activities:
Merchandise income 446,341 - 446,341
Investments 1,695 - 1,695
Total income 8,243,006 1,104,554 9,347,560
EXPENDITURE ON:
Raising funds 3,379,988 - 3,379,988
Charitable activities
Information and support 1,592,854 51,271 1,644,125
Campaigning & awareness 1,459,966 37,503 1,497,469
Research 2,502,908 61,595 2,564,503
Total expenditure 8,935,716 150,369 9,086,085
Net income/(expenditure) (692,710) 954,185 261,475
Funds opening balance 5,977,417 66,233 6,043,650
Transfers between funds 944,500 (944,500) -
Funds closing balance 6,229,207 75,918 6,305,125
**----- End of picture text -----**
## 17. Comparative (prior year) expenditure
|17. Comparative (prior year) expenditure|17. Comparative (prior year) expenditure|17. Comparative (prior year) expenditure|17. Comparative (prior year) expenditure|17. Comparative (prior year) expenditure|
|---|---|---|---|---|
|**DIRECT**
**COSTS**
**2022**
**£**
**GRANTS**
**AWARDED**
**2022**
**£**
**SUPPORT**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|||||
||||||
|**Raising funds**
2,721,348
-
658,640
3,379,988
2,284,272|||||
|**Charitable activities**|||||
|Information and support
1,035,426
-
608,699
1,644,125
1,308,212|||||
|Campaigning & awareness
863,355
-
634,114
1,497,469
1,309,649|||||
|Research
163,445
1,801,677
599,381
2,564,503
745,538|||||
|**4,783,574**|**1,801,677**|**2,500,834**|**9,086,085**|**5,647,671**|
## Comparative (prior year) support costs
|**STAFF**
**COSTS**
**2022**
**£**
**PREMISES &**
**OFFICE COSTS**
**2022**
**£**
**OTHER**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|**STAFF**
**COSTS**
**2022**
**£**
**PREMISES &**
**OFFICE COSTS**
**2022**
**£**
**OTHER**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|**STAFF**
**COSTS**
**2022**
**£**
**PREMISES &**
**OFFICE COSTS**
**2022**
**£**
**OTHER**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|**STAFF**
**COSTS**
**2022**
**£**
**PREMISES &**
**OFFICE COSTS**
**2022**
**£**
**OTHER**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|**STAFF**
**COSTS**
**2022**
**£**
**PREMISES &**
**OFFICE COSTS**
**2022**
**£**
**OTHER**
**COSTS**
**2022**
**£**
**TOTAL**
**2022**
**£**
**TOTAL**
**2021**
**£**|
|---|---|---|---|---|
||||||
|**Cost of raising funds**
333,972
163,479
161,189
658,640
422,465|||||
|**Charitable activities**|||||
|Information and support
284,031
163,479
161,189
608,699
376,238|||||
|Campaigning & awareness
309,446
163,479
161,189
634,114
400,640|||||
|Research
274,713
163,479
161,189
599,381
368,240|||||
|**1,202,162**|**653,916**|**644,756**|**2,500,834**|**1,567,583**|
Support costs have been allocated on the basis of staff time spent on each activity. Governance costs of £24,431 (2021: £9,432) are within support costs.
77
76
Financial Statements
Annual Report and Financial Statements for the year ended 31st March 2023
## 18. Comparative (prior year) analysis of net assets between funds
|18. Comparative (prior year) analysis of net assets
between funds|18. Comparative (prior year) analysis of net assets
between funds|18. Comparative (prior year) analysis of net assets
between funds|
|---|---|---|
|**GENERAL**
**FUNDS**
**2022**
**£**
**RESTRICTED**
**FUNDS**
**2022**
**£**
**TOTAL**
**FUNDS**
**2022**
**£**
Tangible fxed assets
365,264
-
365,264
Net current assets
5,863,943
75,918
5,939,861
Net assets at 31 March 2021
**6,229,207**
**75,918**
**6,305,125**|||
||75,918|5,939,861|
||**75,918**|**6,305,125**|
## 19. Comparative (prior year) movement in funds
|**AT 31 MARCH**
**2021**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2022**
**£**|**AT 31 MARCH**
**2021**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2022**
**£**|**AT 31 MARCH**
**2021**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2022**
**£**|**AT 31 MARCH**
**2021**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2022**
**£**|**AT 31 MARCH**
**2021**
**£**
**INCOME**
**£**
**EXPENDITURE**
**£**
**TRANSFERS**
**£**
**AT 31 MARCH**
**2022**
**£**|
|---|---|---|---|---|
||||||
|**Unrestricted funds:**
**General funds:**|||||
|Operating Contingency
1,192,000
-
-
-
1,192,000|||||
|Unrestricted reserves
879,482
8,243,006
(7,134,039)
(855,500)
1,132,949|||||
|**Total General Funds**
**2,071,482**|**8,243,006**|**(7,134,039)**|**(855,500)**|**2,324,949**|
|**Designated Funds:**|||||
|Future research and expansion
3,905,935
-
(1,801,677)
1,800,000
3,904,258|||||
|**Total Designated Funds**
**3,905,935**|**-**|**(1,801,677)**|**1,800,000**|**3,904,258**|
|**AT 31 MARCH**
**2021**
**£**|**INCOME**
**£**|**EXPENDITURE**
**£**|**TRANSFERS**
**£**|**AT 31 MARCH**
**2022**
**£**|
|---|---|---|---|---|
||||||
|**Restricted funds**
Nicki’s Smile
66,233|7,188|-|-|73,421|
|Future Leaders Fund General
-|-|-|-|-|
|Future Leaders Fund Cambridge
-|156,250|-|(156,250)|-|
|Future Leaders Acadamy Beatson
-|48,701|-|(48,701)|-|
|Future Leader - D Whyte
-|-|-|-|-|
|General Research
-|61,595|(61,595)|-|-|
|Grand Challenge
-|300|-|(300)|-|
|Living with Days in SE
-|-|-|-|-|
|Less Survivable Cancers Taskforce
-|40,000|(37,503)|-|2,497|
|Restricted Northern Ireland
-||-|-|-|
|Research Innovation Fund (RIF)
-|47,123|-|(47,123)|-|
|RIF Chen & Holmes
-|25|-|(25)|-|
|RIF2019 Connell
-|36,000|-|(36,000)|-|
|RIF2019 Gail Van ter Haar
-|27,382|-|(27,382)|-|
|RIF2021 Roberts
-|63,000|-|(63,000)|-|
|RIF2020 Tan
-|12,500|-|(12,500)|-|
|RIF2021 Sandnandam
-|107,202|-|(107,202)|-|
|FF2022 Williams
-|153,000|-|(153,000)|-|
|Ride London100 Expanding Services
-|1,011|(1,011)|-|-|
|Ruth Metcalfe Research Fund
-|-|-|-|-|
|Support and Information Service
-|50,260|(50,260)|-|-|
|Support - Easy Read Publications
-|-|-|-|-|
|UCL - Early Diagnosis Project
-|10,000|-|(10,000)|-|
|Early Diagnosis
-|254,080|-|(254,080)|-|
|Early Detection Innovation Workshop
-|16,000|-|(16,000)|-|
|Europak
-|12,937|-|(12,937)|-|
|**Total restricted funds**
**66,233**|**1,104,554**|**(150,369)**|**(944,500)**|**75,918**|
|**Total funds**
**6,043,650**|**9,347,560**|**(9,086,085)**|**-**|**6,305,125**|
79
78
Annual Report and Financial Statements for the year ended 31st March 2023
Remembering our trustee Arthur Calderwood
## Remembering our trustee Arthur Calderwood
Very sadly, in August this year we lost one of our amazing trustees, Arthur Calderwood, to pancreatic cancer. Arthur was passionate about tackling the lack of improvement in survival rates over the last 50 years and, because of his experience, he understood all too clearly the need for early diagnosis and faster treatments.
Arthur brought hugely valuable business skills and expertise to our Board of Trustees and he will be greatly missed. He had an enormous impact on our work. His legacy continues here and with his beloved family and friends who are in our our thoughts at this sad time.
## Reference and administrative details
## **Governing Document**
## **Trustees**
Lynne Walker (Chair until retirement 21 March 2023)
The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association.
Eleanor Phillips (Chair since appointment 21 March 2023)
Daniel Benjamin (Treasurer until 27 June 2023 Retirement 3 October 2023)
## **Company No.**
05658041
Neil Balmer
**----- Start of picture text -----**
Arthur Calderwood
**----- End of picture text -----**
Arthur Calderwood (Deceased 28 August 2023)
Stuart Fletcher (Retirement 27 June 2023)
Iain Frame (Appointed 27 June 2023)
Jeremy Hand (Appointed 27 June 2023) Rima Horton Greg Mueller Dr Naureen Starling
Katie Stotter
Anne Tutt (Treasurer since appointment 27 June 2023)
## **Principle Staff**
Diana Jupp, Chief Executive
## **Status**
The organisation is a charitable company limited by guarantee, incorporated on 19 December 2005 and registered as a charity on 13 January 2006.
## **Charity No.**
1112708 (England & Wales) SC046392 (Scotland)
## **Trading subsidiary**
Pancreatic Cancer UK Trading Limited Company No. 14011291
## **Registered Office of charity and trading entity**
Westminster Tower, 3 Albert Embankment, London SE1 7SP
## **Bankers**
HSBC Bank plc, 8 Canada Square, London E14 5HQ
Barclays Bank plc, 3-5 King Street, Reading, RG1 2HD
## **Auditors**
Haysmacintyre LLP, 10 Queen Street Place, London EC4R 1AG
81 81
80
Remembering our trustee Arthur Calderwood
## **Pancreatic Cancer UK**
Charitable Company, Limited by Guarantee Company No. 5658041 Charity No. 1112708 Registered in England and Wales Scottish charity number SC046392
82